Concepedia

Juleen Gayed

JG

5

Publications

198

Citations

5

H-Index

2011

Active since

Affiliations

BioNTech (Germany)(Current)

Pfizer (United States)

Pfizer (United Kingdom)

The University of Texas Medical Branch at Galveston

Juleen Gayed is an author at BioNTech (Germany) specializing in humoral immunity, medicine, and vaccine development.

ORCID

Top concepts

Publications per year

2011–2024

5

Publications

5

Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years

Patricia Winokur, Juleen Gayed, David Fitz-Patrick et al. · New England Journal of Medicine · 2023 · 120 citations · Full text

Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial

Juleen Gayed, Oyeniyi Diya, Francine S. Lowry et al. · Vaccines · 2024 · 36 citations · Full text

Comparison of the effects of levofloxacin on QT/QTc interval assessed in both healthy Japanese and Caucasian subjects

Atsushi Sugiyama, Yuji Nakamura, Satomi Nishimura et al. · British Journal of Clinical Pharmacology · 2011 · 18 citations · Full text

Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial

Juleen Gayed, Oyeniyi Diya, Francine S. Lowry et al. · Preprints.org · 2024 · 13 citations · Full text

, , +15

Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial

Juleen Gayed, Vishva Bangad, Xia Xu et al. · Vaccines · 2024 · 11 citations · Full text

Rows per page

1–5 of 5